A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer

Jason B. Nikas, Janet T. Lee, Elizabeth D. Maring, Jill Washechek-Aletto, Donna Felmlee-Devine, Ruth A. Johnson, Thomas Christopher Smyrk, Patrick S. Tawadros, Lisa Allyn Boardman, Clifford J. Steer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

An important determinant of the pathogenesis and prognosis of various diseases is inherited genetic variation. Single-nucleotide polymorphisms (SNPs), variations at a single base position, have been identified in both protein-coding and noncoding DNA sequences, but the vast majority of millions of those variants are far from being functionally understood. Here we show that a common variant in the gene MTHFR [rs1801133 (C>T)] not only influences response to neoadjuvant chemoradiotherapy in patients with rectal cancer, but it also influences recurrence of the disease itself. More specifically, patients with the homozygous ancestral (wild type) genotype (C/C) were 2.91 times more likely (291% increased benefit) to respond to neoadjuvant chemoradiotherapy {95% CI: [1.23, 6.89]; P=0.0150} and 3.25 times more likely (325% increased benefit) not to experience recurrence of the disease {95% CI: [1.37, 7.72]; P=0.0079} than patients with either the heterozygous (C/T) or the homozygous mutation (T/T) genotype. These results identify MTHFR as an important genetic marker and open up new, pharmacogenomic strategies in the treatment and management of rectal cancer.

Original languageEnglish (US)
Pages (from-to)3231-3240
Number of pages10
JournalAmerican Journal of Cancer Research
Volume5
Issue number10
StatePublished - 2015

Fingerprint

Chemoradiotherapy
Rectal Neoplasms
Recurrence
Genotype
Pharmacogenetics
Genetic Markers
Single Nucleotide Polymorphism
Mutation
Genes
Proteins
Therapeutics

Keywords

  • Genetic variation
  • MTHFR single nucleotide polymorphism
  • Personalized medicine
  • Rectal cancer
  • Recurrence of rectal cancer
  • Response to chemoradiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Nikas, J. B., Lee, J. T., Maring, E. D., Washechek-Aletto, J., Felmlee-Devine, D., Johnson, R. A., ... Steer, C. J. (2015). A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer. American Journal of Cancer Research, 5(10), 3231-3240.

A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer. / Nikas, Jason B.; Lee, Janet T.; Maring, Elizabeth D.; Washechek-Aletto, Jill; Felmlee-Devine, Donna; Johnson, Ruth A.; Smyrk, Thomas Christopher; Tawadros, Patrick S.; Boardman, Lisa Allyn; Steer, Clifford J.

In: American Journal of Cancer Research, Vol. 5, No. 10, 2015, p. 3231-3240.

Research output: Contribution to journalArticle

Nikas, JB, Lee, JT, Maring, ED, Washechek-Aletto, J, Felmlee-Devine, D, Johnson, RA, Smyrk, TC, Tawadros, PS, Boardman, LA & Steer, CJ 2015, 'A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer', American Journal of Cancer Research, vol. 5, no. 10, pp. 3231-3240.
Nikas JB, Lee JT, Maring ED, Washechek-Aletto J, Felmlee-Devine D, Johnson RA et al. A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer. American Journal of Cancer Research. 2015;5(10):3231-3240.
Nikas, Jason B. ; Lee, Janet T. ; Maring, Elizabeth D. ; Washechek-Aletto, Jill ; Felmlee-Devine, Donna ; Johnson, Ruth A. ; Smyrk, Thomas Christopher ; Tawadros, Patrick S. ; Boardman, Lisa Allyn ; Steer, Clifford J. / A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer. In: American Journal of Cancer Research. 2015 ; Vol. 5, No. 10. pp. 3231-3240.
@article{efb738a6a2554c7c9741f930aa021394,
title = "A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer",
abstract = "An important determinant of the pathogenesis and prognosis of various diseases is inherited genetic variation. Single-nucleotide polymorphisms (SNPs), variations at a single base position, have been identified in both protein-coding and noncoding DNA sequences, but the vast majority of millions of those variants are far from being functionally understood. Here we show that a common variant in the gene MTHFR [rs1801133 (C>T)] not only influences response to neoadjuvant chemoradiotherapy in patients with rectal cancer, but it also influences recurrence of the disease itself. More specifically, patients with the homozygous ancestral (wild type) genotype (C/C) were 2.91 times more likely (291{\%} increased benefit) to respond to neoadjuvant chemoradiotherapy {95{\%} CI: [1.23, 6.89]; P=0.0150} and 3.25 times more likely (325{\%} increased benefit) not to experience recurrence of the disease {95{\%} CI: [1.37, 7.72]; P=0.0079} than patients with either the heterozygous (C/T) or the homozygous mutation (T/T) genotype. These results identify MTHFR as an important genetic marker and open up new, pharmacogenomic strategies in the treatment and management of rectal cancer.",
keywords = "Genetic variation, MTHFR single nucleotide polymorphism, Personalized medicine, Rectal cancer, Recurrence of rectal cancer, Response to chemoradiotherapy",
author = "Nikas, {Jason B.} and Lee, {Janet T.} and Maring, {Elizabeth D.} and Jill Washechek-Aletto and Donna Felmlee-Devine and Johnson, {Ruth A.} and Smyrk, {Thomas Christopher} and Tawadros, {Patrick S.} and Boardman, {Lisa Allyn} and Steer, {Clifford J.}",
year = "2015",
language = "English (US)",
volume = "5",
pages = "3231--3240",
journal = "American Journal of Cancer Research",
issn = "2156-6976",
publisher = "e-Century Publishing Corporation",
number = "10",

}

TY - JOUR

T1 - A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer

AU - Nikas, Jason B.

AU - Lee, Janet T.

AU - Maring, Elizabeth D.

AU - Washechek-Aletto, Jill

AU - Felmlee-Devine, Donna

AU - Johnson, Ruth A.

AU - Smyrk, Thomas Christopher

AU - Tawadros, Patrick S.

AU - Boardman, Lisa Allyn

AU - Steer, Clifford J.

PY - 2015

Y1 - 2015

N2 - An important determinant of the pathogenesis and prognosis of various diseases is inherited genetic variation. Single-nucleotide polymorphisms (SNPs), variations at a single base position, have been identified in both protein-coding and noncoding DNA sequences, but the vast majority of millions of those variants are far from being functionally understood. Here we show that a common variant in the gene MTHFR [rs1801133 (C>T)] not only influences response to neoadjuvant chemoradiotherapy in patients with rectal cancer, but it also influences recurrence of the disease itself. More specifically, patients with the homozygous ancestral (wild type) genotype (C/C) were 2.91 times more likely (291% increased benefit) to respond to neoadjuvant chemoradiotherapy {95% CI: [1.23, 6.89]; P=0.0150} and 3.25 times more likely (325% increased benefit) not to experience recurrence of the disease {95% CI: [1.37, 7.72]; P=0.0079} than patients with either the heterozygous (C/T) or the homozygous mutation (T/T) genotype. These results identify MTHFR as an important genetic marker and open up new, pharmacogenomic strategies in the treatment and management of rectal cancer.

AB - An important determinant of the pathogenesis and prognosis of various diseases is inherited genetic variation. Single-nucleotide polymorphisms (SNPs), variations at a single base position, have been identified in both protein-coding and noncoding DNA sequences, but the vast majority of millions of those variants are far from being functionally understood. Here we show that a common variant in the gene MTHFR [rs1801133 (C>T)] not only influences response to neoadjuvant chemoradiotherapy in patients with rectal cancer, but it also influences recurrence of the disease itself. More specifically, patients with the homozygous ancestral (wild type) genotype (C/C) were 2.91 times more likely (291% increased benefit) to respond to neoadjuvant chemoradiotherapy {95% CI: [1.23, 6.89]; P=0.0150} and 3.25 times more likely (325% increased benefit) not to experience recurrence of the disease {95% CI: [1.37, 7.72]; P=0.0079} than patients with either the heterozygous (C/T) or the homozygous mutation (T/T) genotype. These results identify MTHFR as an important genetic marker and open up new, pharmacogenomic strategies in the treatment and management of rectal cancer.

KW - Genetic variation

KW - MTHFR single nucleotide polymorphism

KW - Personalized medicine

KW - Rectal cancer

KW - Recurrence of rectal cancer

KW - Response to chemoradiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85006197351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006197351&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85006197351

VL - 5

SP - 3231

EP - 3240

JO - American Journal of Cancer Research

JF - American Journal of Cancer Research

SN - 2156-6976

IS - 10

ER -